Prostate-specific antigen testing and prostate cancer screening. 2010

Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
Department of Urology, New York University School of Medicine (NYU), New York University Hospital, 150 East 32nd Street, New York, NY 10016, USA. bdjavan@hotmail.com

Prostate specific antigen (PSA) screening is an integral part of current screening for prostate cancer. Together with digital rectal examinations, it is recommended annually by the American Cancer Society. PSA screening has resulted in a significant stage migration in the past decades. Different forms of PSA, including free PSA, volume adjusted, complexed, intact, or pro-PSA, are being used in the screening process. Other aspects of the screening process include age at diagnosis, survival, overdiagnosis, and overtreatment. Recent studies have cast doubt on whether PSA screening positively affects mortality and how the quality of life of patients may be affected by screening. Future considerations include the need for more longitudinal studies as well as further study of the PSA components that may become more relevant in the future.

UI MeSH Term Description Entries
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011320 Primary Health Care Care which provides integrated, accessible health care services by clinicians who are accountable for addressing a large majority of personal health care needs, developing a sustained partnership with patients, and practicing in the context of family and community. (JAMA 1995;273(3):192) Primary Care,Primary Healthcare,Care, Primary,Care, Primary Health,Health Care, Primary,Healthcare, Primary
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein
D017677 Age Distribution The frequency of different ages or age groups in a given population. The distribution may refer to either how many or what proportion of the group. The population is usually patients with a specific disease but the concept is not restricted to humans and is not restricted to medicine. Age Distributions,Distribution, Age,Distributions, Age

Related Publications

Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
August 2015, American journal of preventive medicine,
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
April 2021, The British journal of general practice : the journal of the Royal College of General Practitioners,
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
April 2021, The British journal of general practice : the journal of the Royal College of General Practitioners,
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
April 2011, American family physician,
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
February 2004, Minerva medica,
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
January 2016, Mayo Clinic proceedings,
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
August 2009, Evidence-based medicine,
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
October 2002, BMJ (Clinical research ed.),
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
December 1998, Annals of oncology : official journal of the European Society for Medical Oncology,
Bob Djavan, and Elisabeth Eckersberger, and Julia Finkelstein, and Helen Sadri, and Samir S Taneja, and Herbert Lepor
January 2022, JAMA oncology,
Copied contents to your clipboard!